Clinical trials: Pathologic Neovascularization
Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.
- Conditions
- Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
- Trial name
- NCT03834753
- Testing
- bevacizumab, ranibizumab
- Where
- 50 sites in United States
- Volunteers
- 228 people
- Sponsor
- Outlook Therapeutics, Inc.
Age-Related Macular Degeneration, Neovascularization, Choroidal
Impact of Non-Exudative Type 1 MNV on AMD Progression
The overall goal of the proposed research project is to provide evidence that a specific subtype of neovascularization that may develop in eyes with age-related macular degeneration (AMD) prevents vision loss.
- Trial name
- NCT06125977
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- University of Utah
Pre-eclampsia, Pre-Term
Study of Pregnancy Pathologies Associated With Placental Abnormalities
Pregnancy pathologies can occur from implantation until childbirth. The investigators are interested in the development mechanisms of these pathologies and aim to develop therapies to treat them.
- Conditions
- Pre-eclampsia, Pre-Term, Fetal Growth Retardation
- Trial name
- NCT05188066
- Testing
- Histology
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Choroidal Neovascularization, Degenerative Myopia
Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD)
The purpose of this study is to see if the drug bevacizumab is safe and effective to use for people with choroidal neovascularization (CNV).
- Conditions
- Choroidal Neovascularization, Degenerative Myopia, Pathological Myopia
- Trial name
- NCT00407719
- Testing
- Bevacizumab
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Stress Urinary Incontinence, Ultrasound
Urethral Vascularization and Urodynamics
The urethra plays a crucial role in maintaining urinary continence. Its complex blood supply is still not well understood. Particularly in the context of urethral pressure.
- Conditions
- Stress Urinary Incontinence, Ultrasound, Vascularisation, Urodynamic Exam
- Trial name
- UVASC (NCT07185698)
- Testing
- 3D Ultrasound
- Where
- Switzerland
- Volunteers
- 70 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Cystic Fibrosis With Mild to Moderate Lung Disease, CMRI of Lung Perfusion
Sildenafil Trial in Children and Young Adults With CF
Cystic Fibrosis (CF), the most common inherited disease in Caucasians, is characterized by chronic pulmonary inflammation and progressive loss of gas exchange units that eventually results in respiratory failure.
- Conditions
- Cystic Fibrosis With Mild to Moderate Lung Disease, CMRI of Lung Perfusion, Lung Perfusion, Lung Vascularization
- Trial name
- NCT01194232
- Testing
- Sildenafil
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Choroidal Neovascularization, Macular Degeneration
Photodynamic and Pharmacologic Treatment of CNV
The goal of this pilot study is to validate the use of the combination of Lucentis (ranibizumab) and Visudyne (verteporfin) in the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration…
- Trial name
- PBS (NCT00570193)
- Testing
- verteporfin (Visudyne), ranibizumab (Lucentis)
- Volunteers
- 41 people
- Sponsor
- Mid-Atlantic Retina Consultations, Inc.
Kidney Neoplasm, Lung Neoplasm
Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer
The purposes of this study are fourfold. It will 1) determine what dose of interleukin-12 (IL-12) and interleukin-2 (IL-2) combination therapy can be given safely to patients with advanced cancer; 2) evaluate the side effects of…
- Conditions
- Kidney Neoplasm, Lung Neoplasm, Sarcoma, Breast Neoplasm
- Trial name
- NCT00005655
- Testing
- rh IL-12, rh IL-2
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Choroidal Neovascularization, Age-Related Maculopathy
Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)
The study will evaluate the safety and efficacy of the intravitreal dexamethasone implant as adjunctive therapy to Anti-VEGF treatment in the study eye of treatment naïve subjects with choroidal neovascularization secondary to…
- Trial name
- NCT00775411
- Testing
- dexamethasone, ranibizumab
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 44 people
- Sponsor
- Allergan
Corneal Neovascularization
Corneal Crosslinking for Treatment of Corneal Neovascularization
The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.
- Trial name
- NCT04787471
- Testing
- 30 minute photoactivation of riboflavin 0.1%, 10 minute photoactivation of riboflavin 0.1%
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Price Vision Group
Myopic Choroidal Neovascular Membrane
Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia
Intravitreal pegaptanib for treatment of choroidal neovascularisation secondary to pathologic myopia
- Trial name
- INGECT (NCT01218230)
- Testing
- Intravitreal Pegaptanib
- Where
- India
- Sponsor
- L.V. Prasad Eye Institute
Ocular Histoplasmosis Syndrome
Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome
The purpose of this study is to evaluate the safety and effectiveness of intravitreal ranibizumab (Lucentis) in patients with fluid and blood leakage in their eyes due to ocular histoplasmosis.
- Trial name
- IVL for OHS (NCT00955630)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Retina Associates of Kentucky
Diabetic Macular Edema, Age-Related Macular Degeneration
Effect of Corona Virus on Intravitreal Injections
During pandemic of corona virus, patients compliance may be affected. We aim to study the factors lead to unregulated visits and its implications on the final visual outcome.
- Conditions
- Diabetic Macular Edema, Age-Related Macular Degeneration, Choroidal Neovascularization, Myopic Choroidal Neovascularisation
- Trial name
- NCT05494775
- Testing
- Anti-vascular endothelial growth factors (Anti-VEGFs)
- Where
- Egypt
- Volunteers
- 250 people
- Sponsor
- Benha University
Polypoidal Choroidal Vasculopathy
Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)
This is a 12 month study of monthly injections of ranibizumab in subjects with polypoidal choroidal vasculopathy as diagnosed by fluoresceins/indocyanine green (FA/ICG) angiography.
- Trial name
- PEARL (NCT00424710)
- Testing
- ranibizumab intravitreal injection
- Where
- 2 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Hawaii Pacific Health
AMD, Age-related Macular Degeneration
Resveratrol for Exudative Age-Related Macular Degeneration
This is an interventional, prospective, randomized, comparative monocentric study aiming to evaluate the safety and efficacy of Resveratrol to reduce the progression of exudative Age-Related Macular Degeneration.
- Conditions
- AMD, Age-related Macular Degeneration, Choroidal Neovascularisation
- Trial name
- AGED (NCT02625376)
- Testing
- Resvega, Trans-Resveratrol
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Poitiers University Hospital
Pseudoxanthoma Elasticum
Evolution of Visual Impairment During Pseudoxanthoma Elasticum
Pseudoxanthoma elasticum is a disease whom frequency is estimated about 1/50000 to 1/100 000. There is a female preponderance with a sex-ratio of 2:1.
- Trial name
- NCT00555113
- Where
- France
- Volunteers
- 38 people
- Sponsor
- European Georges Pompidou Hospital
Polypoidal Choroidal Vasculopathy
Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy
Monthly, continuous anti-vegf therapy for patients presenting with active polypoidal choroidal vasculopathy. Two arms, treatment naive and previously treated with an FDA approved anti-VEGF therapy, will be randomized and dosed…
- Trial name
- PEARL2 (NCT01248117)
- Testing
- ranibizumab 2.0mg
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Retina Consultants of Hawaii
Arterial Occlusive Diseases
Safety and Feasibility Study of Autologous Bone Marrow Cell Transplantation in Patients With Peripheral Arterial Occlusive Disease (PAOD)
Patients with peripheral artery disease, stage III or IV who are not candidates for interventional or operative therapy should be treated with intraarterial progenitor cell therapy (autologous bone marrow cells) in a randomized…
- Trial name
- NCT00282646
- Testing
- intraarterial stem cell therapy, Stem cells
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Wet Age-Related Macular Degeneration
Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration
This study evaluates the tolerability and safety of a single intravenous infusion of ACZ885. It also explores the efficacy of the compound in central macular edema and visual acuity in patients with wet age-related macular edema.
- Trial name
- NCT00503022
- Testing
- ACZ885
- Where
- 8 sites in Switzerland, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Novartis
Choroidal Neovascularization, Mineralocorticoid Excess
Biomarkers and Choroidal Neovascularization
The aim of the study is to find biomarkers in the blood and aqueous humor of patients with type 1 choroidal neovascularization and correlate them with the response to anti-VEGF treatment.
- Trial name
- BioNéoRet (NCT04439708)
- Testing
- Blood and aqueous humor biomarker of treatment response
- Where
- 2 sites in France
- Volunteers
- 250 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France